{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=16",
    "query": {
      "condition": "Vector",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 687,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T23:27:04.043Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02366013",
      "title": "Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "rcAd26.MOS1.HIV-Env 1x10^8 vp",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rcAd26.MOS1.HIV-Env 1x10^9 vp",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rcAd26.MOS1.HIV-Env 1x10^10 vp",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rcAd26.MOS1.HIV-Env 1x10^11 vp",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 22,
      "start_date": "2015-01",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-21",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02366013"
    },
    {
      "nct_id": "NCT03278873",
      "title": "Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Achromatopsia"
      ],
      "interventions": [
        {
          "name": "Prior exposure to AAV-CNGA3 or AAV-CNGB3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MeiraGTx UK II Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "3 Years to 100 Years"
      },
      "enrollment_count": 34,
      "start_date": "2017-06-29",
      "completion_date": "2024-04-04",
      "has_results": true,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03278873"
    },
    {
      "nct_id": "NCT01524562",
      "title": "HIV Accelerated Liver Disease in Uganda",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fibrosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 786,
      "start_date": "2011-12-20",
      "completion_date": "2019-12-17",
      "has_results": false,
      "last_update_posted_date": "2020-01-06",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524562"
    },
    {
      "nct_id": "NCT01246479",
      "title": "Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Japanese Encephalitis"
      ],
      "interventions": [
        {
          "name": "Blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "IC51 has given in the parent study IC51-322",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Valneva Austria GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Months",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "9 Months to 20 Years"
      },
      "enrollment_count": 23,
      "start_date": "2010-10",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2020-03-18",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01246479"
    },
    {
      "nct_id": "NCT00347555",
      "title": "Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum Malaria"
      ],
      "interventions": [
        {
          "name": "Aluminum Phosphate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "EBA-175 RII-NG Malaria Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 80,
      "start_date": "2006-05",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2013-04-12",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00347555"
    },
    {
      "nct_id": "NCT01666652",
      "title": "A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "4 µg TDENV-PIV with Alum adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1 µg TDENV-PIV with AS03B1 adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate buffered saline",
          "type": "OTHER"
        },
        {
          "name": "1 µg TDENV-PIV with Alum adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1 µg TDENV-PIV with AS01E1 adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 100,
      "start_date": "2012-09",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2019-01-25",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666652"
    },
    {
      "nct_id": "NCT07732400",
      "title": "A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metabolic Dysfunction-associated Steatohepatitis (MASH)"
      ],
      "interventions": [
        {
          "name": "VV-14303",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Kriya Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 56,
      "start_date": "2026-07-30",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 2,
      "location_summary": "Chandler, Arizona • Lady Lake, Florida",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Lady Lake",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07732400"
    },
    {
      "nct_id": "NCT02446626",
      "title": "Xenodiagnosis After Antibiotic Treatment for Lyme Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lyme Disease"
      ],
      "interventions": [
        {
          "name": "Skin biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "Xenodiagnosis",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2015-07-24",
      "completion_date": "2022-05-04",
      "has_results": true,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 5,
      "location_summary": "Storrs, Connecticut • Bethesda, Maryland • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Storrs",
          "state": "Connecticut"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02446626"
    },
    {
      "nct_id": "NCT03776994",
      "title": "Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Encephalitis",
        "Encephalitis, Viral",
        "Infectious Encephalitis",
        "Virus Diseases",
        "Encephalomyelitis, Venezuelan Equine",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Central Nervous System Viral Diseases",
        "Alphavirus Infections",
        "Togaviridae Infections",
        "RNA Virus Infections",
        "Central Nervous System Infections",
        "Encephalomyelitis",
        "Physiological Effects of Drugs",
        "Vaccines",
        "Encephalomyelitis, Equine",
        "Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "Vaccinations on Day 0, Day 28, and Day 140",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "SRI International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2018-07-17",
      "completion_date": "2021-04",
      "has_results": false,
      "last_update_posted_date": "2021-02-23",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 1,
      "location_summary": "Plymouth, Michigan",
      "locations": [
        {
          "city": "Plymouth",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03776994"
    },
    {
      "nct_id": "NCT06693986",
      "title": "Adenovirus (RGDCRAdCOX2F)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of Pancreas"
      ],
      "interventions": [
        {
          "name": "Replicative Adenovirus Vector (RGDCRAdCOX2F)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-12-27",
      "completion_date": "2029-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-23T23:27:04.043Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06693986"
    }
  ]
}